Biogen Turns In Robust Quarter, Fueled By Avonex; Late-Stage Commercial Catalysts Abound

In the second quarter, Biogen demonstrated a continuing ability to milk revenue from established MS products while it prepares to launch a wave of potentially market-shifting NMEs.

Biogen Inc. management reported progress across its portfolio, showing unexpectedly strong growth in Avonex (interferon beta-1a), flat sales from Tysabri (natalizumab), and an incipient but growing share from Fampyra (prolonged-release fampridine tablets), the treatment for walking impairment in multiple sclerosis patients for which Biogen licensed ex-US rights from Acorda Therapeutics Inc.[See Deal].

In a sign of the new commercial landscape with which companies must now contend, European austerity, drug sale tenders in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet